These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26507307)

  • 1. Counterpoint: the treatment decision design.
    Brookhart MA
    Am J Epidemiol; 2015 Nov; 182(10):840-5. PubMed ID: 26507307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The limitations of observation studies for decision making regarding drugs efficacy and safety.
    Gueyffier F; Cucherat M
    Therapie; 2019 Apr; 74(2):181-185. PubMed ID: 30514576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication safety research by observational study design.
    Lao KS; Chui CS; Man KK; Lau WC; Chan EW; Wong IC
    Int J Clin Pharm; 2016 Jun; 38(3):676-84. PubMed ID: 27003827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
    Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
    Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counterpoint: epidemiology to guide decision-making: moving away from practice-free research.
    Hernán MA
    Am J Epidemiol; 2015 Nov; 182(10):834-9. PubMed ID: 26507306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs.
    Etminan M; Samii A
    Pharmacotherapy; 2004 Aug; 24(8):964-9. PubMed ID: 15338844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding the Evidence Base: Comparing Randomized Controlled Trials and Observational Studies of Statins.
    Atar D; Ong S; Lansberg PJ
    Am J Ther; 2015; 22(5):e141-50. PubMed ID: 22487773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.
    Roberts AW; Dusetzina SB; Farley JF
    J Comp Eff Res; 2015 Jan; 4(1):27-35. PubMed ID: 25565067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making.
    Caparrotta TM; Dear JW; Colhoun HM; Webb DJ
    Br J Clin Pharmacol; 2019 Sep; 85(9):1907-1924. PubMed ID: 31206748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study designs in paediatric pharmacoepidemiology.
    Verhamme K; Sturkenboom M
    Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():67-74. PubMed ID: 21107830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for time-varying exposure related problems in pharmacoepidemiology: An overview.
    Pazzagli L; Linder M; Zhang M; Vago E; Stang P; Myers D; Andersen M; Bahmanyar S
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):148-160. PubMed ID: 29285840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of expanding the look-back period to all available data in the assessment of covariates.
    Nakasian SS; Rassen JA; Franklin JM
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):890-899. PubMed ID: 28397352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on clinical trials for the prevention of acute kidney injury in patients undergoing cardiac surgery.
    Alsabbagh MM; Asmar A; Ejaz NI; Aiyer RK; Kambhampati G; Ejaz AA
    Am J Surg; 2013 Jul; 206(1):86-95. PubMed ID: 23411349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research.
    Targownik LE; Suissa S
    Am J Gastroenterol; 2015 Dec; 110(12):1647-50. PubMed ID: 26323186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invited Commentary: The Prevalent New-User Design in Pharmacoepidemiology-Challenges and Opportunities.
    Filion KB; Yu YH
    Am J Epidemiol; 2021 Jul; 190(7):1349-1352. PubMed ID: 33350439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An application of propensity score matching using claims data.
    Seeger JD; Williams PL; Walker AM
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):465-76. PubMed ID: 15651087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active-comparator design and new-user design in observational studies.
    Yoshida K; Solomon DH; Kim SC
    Nat Rev Rheumatol; 2015 Jul; 11(7):437-41. PubMed ID: 25800216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
    García Rodríguez LA; Herings R; Johansson S
    Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.